BR9911917A - Composições compreendendo análogos de gaba e cafeìna - Google Patents

Composições compreendendo análogos de gaba e cafeìna

Info

Publication number
BR9911917A
BR9911917A BR9911917-0A BR9911917A BR9911917A BR 9911917 A BR9911917 A BR 9911917A BR 9911917 A BR9911917 A BR 9911917A BR 9911917 A BR9911917 A BR 9911917A
Authority
BR
Brazil
Prior art keywords
compositions
gaba
caffeine
analogs
caffeine analogs
Prior art date
Application number
BR9911917-0A
Other languages
English (en)
Inventor
Leslie Magnus
Catherine A Segal
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BR9911917A publication Critical patent/BR9911917A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçõES COMPREENDENDO ANáLOGOS DE GABA E CAFEìNA"<D>. Composições que compreendem um análogo do GABA, como a gabapentina ou a pregabalina em combinação com cafeína estão descritas. As composições são usadas para o tratamento da dor em mamíferos.
BR9911917-0A 1998-07-09 1999-06-18 Composições compreendendo análogos de gaba e cafeìna BR9911917A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9213198P 1998-07-09 1998-07-09
PCT/US1999/013670 WO2000002562A1 (en) 1998-07-09 1999-06-18 Compositions comprising gaba analogs and caffeine

Publications (1)

Publication Number Publication Date
BR9911917A true BR9911917A (pt) 2001-03-27

Family

ID=22231777

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9911917-0A BR9911917A (pt) 1998-07-09 1999-06-18 Composições compreendendo análogos de gaba e cafeìna

Country Status (13)

Country Link
US (1) US6326374B1 (pt)
EP (1) EP1094817A1 (pt)
JP (1) JP2002520286A (pt)
KR (1) KR20010071777A (pt)
AU (1) AU772156B2 (pt)
BR (1) BR9911917A (pt)
CA (1) CA2332915C (pt)
ID (1) ID28277A (pt)
NO (1) NO20010119L (pt)
NZ (1) NZ508490A (pt)
PL (1) PL345340A1 (pt)
WO (1) WO2000002562A1 (pt)
ZA (1) ZA200007168B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332762A (en) 1996-07-24 2000-09-29 Warner Lambert Co Isobutylgaba and its derivatives for the treatment of pain
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
JP2002541215A (ja) * 1999-04-09 2002-12-03 ユーロ−セルティック エス． ア． ナトリウムチャネル遮断薬組成物およびその使用
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003020273A2 (en) * 2001-09-03 2003-03-13 Newron Pharmaceuticals Spa Pharmaceutical composition comprising gabapentin or an analogue thereof and an $g(a)-aminoamide and its analgesic use
JP2007528893A (ja) * 2004-03-12 2007-10-18 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｃ１対称ビスホスフィンリガンド及びプレガバリンの不斉合成におけるそれらの使用
BRPI0508998A (pt) * 2004-04-01 2007-09-04 Warner Lambert Co preparação de fosfolanos p-quirogênicos e seu uso em sìntese assimétrica
ME01067B (me) * 2004-06-21 2012-10-20 Warner Lambert Co Dobijanje pregabalina i srodnih jedinjenja
AU2005282028B2 (en) * 2004-09-10 2011-03-24 Newron Pharmaceuticals S.P.A. (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators
CA2629065C (en) 2005-12-22 2013-08-06 Newron Pharmaceuticals S.P.A. 2 -phenylethylamino derivatives as calcium and/or sodium channel modulators
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
CH699327B1 (de) 2007-02-14 2010-03-15 Oerlikon Heberlein Temco Wattw Vorrichtung zum gleichzeitigen Behandeln von mehreren multifilen Fäden.
WO2009021058A2 (en) 2007-08-06 2009-02-12 Trinity Labortories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2011141923A2 (en) 2010-05-14 2011-11-17 Lupin Limited Improved synthesis of optically pure (s) - 3-cyano-5-methyl-hexanoic acid alkyl ester, an intermediate of (s)- pregabalin
WO2012059797A1 (en) 2010-11-04 2012-05-10 Lupin Limited Process for synthesis of (s) - pregabalin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656177A (en) 1982-07-22 1987-04-07 Analgesic Associates Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5248678A (en) 1992-06-30 1993-09-28 Fractal Laboratories, Inc. Methods for increasing arousal and alertness and for the amelioration of comatose states
EP0717624A1 (en) * 1993-09-07 1996-06-26 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
US5443838A (en) * 1993-09-15 1995-08-22 Koenig, Jr.; Steven M. Nutritional supplementation system
CA2244912C (en) * 1996-03-14 2005-07-12 Warner-Lambert Company Novel substituted cyclic amino acids as pharmaceutical agents
ES2241055T3 (es) 1996-08-23 2005-10-16 Endo Pharmaceuticals Inc Composicion que contiene un anticonvulsionante para tratar el dolor neuropatico.
ATE361909T1 (de) 1996-10-23 2007-06-15 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
DE69832712T2 (de) 1997-09-08 2006-06-22 Warner-Lambert Company Llc Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen

Also Published As

Publication number Publication date
ID28277A (id) 2001-05-10
AU4691099A (en) 2000-02-01
NO20010119D0 (no) 2001-01-08
NO20010119L (no) 2001-01-08
AU772156B2 (en) 2004-04-08
EP1094817A1 (en) 2001-05-02
KR20010071777A (ko) 2001-07-31
PL345340A1 (en) 2001-12-17
NZ508490A (en) 2003-08-29
ZA200007168B (en) 2002-03-04
JP2002520286A (ja) 2002-07-09
CA2332915A1 (en) 2000-01-20
WO2000002562A1 (en) 2000-01-20
US6326374B1 (en) 2001-12-04
CA2332915C (en) 2006-10-24

Similar Documents

Publication Publication Date Title
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
UY24354A1 (es) Composiciones farmacéuticas que contienen epinastina
BR0207961A (pt) Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas
BRPI0411319A (pt) compostos terapeuticamente ativos e sua utilização
BR9808348A (pt) Alimento medicinal para diabéticos
SE9502167L (sv) Insulinanalog-kompositioner
BR9900320A (pt) Composição antimicrobiana
BR9714517A (pt) Cicloalquila, lactama, lactona e compostos correlatos, composições farmacêuticas compreendendo os mesmos e processos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
DE69905170T2 (de) Thiazolopyrimidinderivate
ZA98214B (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1.
DK0705100T3 (da) Terapeutiske substituerede guanidiner
BR0212298A (pt) Composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
AR003589A1 (es) Utilizacion de una cantidad eficaz de al menos un peptido en una composicion cosmetica o para la preparacion de un medicamento destinada paratratar la inflamacion, y un procedimiento de tratamiento cosmetico mediante una composicion cosmetica que contiene a dicho peptido.
BR9913072A (pt) Sistemas de anel azacìclico, composição farmacêutica, e, processo para induzir a analgesia
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
BR0012058A (pt) Combinação sinérgica: gabapentina e pregabalina
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
PT640098E (pt) Gene de coronavirus canino e suas utilizacoesc
ATE344664T1 (de) Verbesserte methode zur eradikation von helicobacter pylori
BR0206087A (pt) Formulação de enxaguamento redutora para uso com ozÈnio no tratamento de cáries dentárias
DE69831737D1 (de) Neurotrypsin
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
EA199700032A1 (ru) Дезинфицирующий состав &#34;велтолен&#34;

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/52, A61K 31/197, A61P 29/00, A61P 25/04

Ipc: A61K 31/52 (2007.10), A61K 31/197 (2007.10), A61P

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.